Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galderma Steps Into Biologics With Chugai Eczema Antibody

Executive Summary

Galderma has acquired most global rights to a first-in-class antibody from Chugai that will both strengthen the Swiss skin specialist's atopic dermatitis portfolio and provide its first biologic therapy.

You may also be interested in...



Galderma’s First-In-Class Biologic Chases Eczema Spoils

Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.

Tech Transfer Roundup: ProQR Partners With Foundation Fighting Blindness On Rare Vision-Loss Disorder

Galderma unveils seven-year partnership with Mount Sinai and Northwestern in atopic dermatitis. Beacon/Takeda and Zealand/UniQuest tie-ups both address gastrointestinal diseases.

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel